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Introduction: After early reports of vandetanib’s efficacy in the 
induction setting, we evaluated the effect of combination docetaxel, 
carboplatin, and vandetanib, followed by maintenance therapy with 
either vandetanib, or placebo on progression-free survival (PFS) in 
patients with advanced non–small-cell lung cancer.
Methods: Patients with advanced non–small-cell lung cancer were ran-
domized to induction docetaxel (75 mg/m2) + carboplatin (area under the 
curve of 6) on day 1 of a 21-day cycle, and daily vandetanib (100 mg/day 
orally) for four cycles, followed by daily vandetanib (300 mg/day orally) 
or placebo until progression. Eligible patients had measurable disease, 
Eastern Cooperative Oncology Group performance status 0 of 1, and no 
prior cytotoxic or targeted agents for advanced disease.
Results: One hundred sixty-two patients were randomized; 158 
began induction treatment. Fifty-eight patients began maintenance 
vandetanib or placebo (median, 3.5 cycles). Median PFS for patients 
randomized to maintenance vandetanib was 4.5 months (95% con-
fidence interval, 3.3–5.8 months), and for patients randomized to 
maintenance placebo was 4.2 months (95% confidence interval, 
2.8–4.9 months). An exploratory analysis showed prolonged PFS for 
patients randomized to vandetanib maintenance (stratified log-rank 
p= 0.07) as also in a multivariate model adjusting for sex and stage 
(p = 0.02). Differences in PFS were not observed among patients 
who began maintenance therapy. Toxicities were similar to other 
studies of these agents.
Conclusion: Neither arm showed improvement over historical 
median PFS of 4.6 months, although patients who began maintenance 
and were randomized to vandetanib had somewhat better outcomes 
than those randomized to placebo. Given its acceptable toxicity pro-
file, there may be a role for vandetanib in maintenance.
Key Words: Vandetanib, Non–small-cell lung cancer, Maintenance 
therapy.
(J Thorac Oncol. 2013;8: 1075-1083)
Lung cancer is the leading cause of cancer-related mortal-ity in the United States, with an estimated 159,480 deaths 
predicted for 2013.1 Over 80% of these patients have non–
small-cell lung cancer (NSCLC); most have advanced disease 
at diagnosis. Patients with advanced disease and good perfor-
mance status (PS) clearly benefit from chemotherapy. Many 
clinical trials testing for the most effective regimen dem-
onstrated that all platinum-based doublets produce similar 
results. Trials with additional agents have been disappointing; 
the majority of these studies demonstrated increased toxicity 
without additional benefit in survival.2–5 The poor outcomes 
associated with advanced NSCLC demonstrate the need for 
continued improvements in treatment.
In recent years, strategies tested targeting the vascular 
endothelial growth factor (VEGF) pathway, and in a phase III 
Eastern Cooperative Oncology Group (ECOG) trial (E4599), 
patients with advanced NSCLC who received carboplatin + 
paclitaxel with bevacizumab6 demonstrated improved median 
overall survival (OS) (p = 0.003) compared with patients who 
received chemotherapy alone.
The epidermal growth factor receptor (EGFR) 
pathway has been yet another therapy target. Studies 
have shown shortened OS in NSCLC patients whose 
tumor overexpresses EGFR.7–9 EGFR inhibitors have 
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demonstrated utility as salvage therapy,10 and more 
recently, as maintenance agents.11 The association between 
EGFR mutations and clinical benefit was also emerging 
at the time the study was designed, although mutation 
status was not being used to select patients for treatment at 
that time.12,13
Given evidence of activity in targeting the VEGF and 
EGFR pathways, investigators tested the simultaneous tar-
geting of both pathways in the previously treated, recurrent 
NSCLC setting14 in a phase I/II trial using bevacizumab plus 
erlotinib. This combination was well tolerated and encourag-
ing levels of activity were observed. On the basis of these 
findings, randomized phase III studies had been launched and 
were nearing completion of accrual at the time this study was 
designed.15,16
Vandetanib is a novel oral tyrosine kinase inhibitor with 
dual activity against both the VEGFR and EGFR pathways. 
Preliminary studies of vandetanib in NSCLC demonstrated 
sufficient activity to warrant further clinical investigations. 
The combination of docetaxel and vandetanib had been stud-
ied in a randomized phase II trial of 127 patients with NSCLC 
who were previously treated and failed first-line therapy for 
metastatic or advanced disease.17 Patients were treated with 
docetaxel alone versus two dosages (300 mg or 100 mg daily 
orally [PO]) of vandetanib. Patients who received docetaxel 
plus vandetanib at 100 mg PO daily had fewer toxicities and 
equal efficacy compared with patients on higher dosage of 
vandetanib, and when compared with docetaxel alone, expe-
rienced prolonged progression-free survival (PFS). We under-
took this study to evaluate the combination of docetaxel + 
carboplatin and vandetanib, followed by maintenance of 
vandetanib or placebo given until disease progression. Given 
the demonstrated value of EGFR-directed chemotherapy for 
maintenance, and the proven value of targeting VEGF, we 
posed the question for the role of this dual inhibitor during 
maintenance.
PATIENTS AND METHODS
Patients and Eligibility Criteria
Eligible patients had primary or recurrent, advanced 
(stage IIIB or IV) NSCLC measurable by Response 
Evaluation Criteria in Solid Tumors criteria (version 1.0).18 
Patients with any histologic subtype were eligible, including 
squamous cell carcinoma. Previous cytotoxic chemotherapy 
or targeted therapy for advanced or metastatic disease was 
not allowed; however, postoperative adjuvant therapy for 
NSCLC was allowed, provided the last dosage was admin-
istered at least a year before randomization, with current 
evidence of disease progression. Other inclusion criteria 
included ECOG PS of 0 or 1, age 18 years or more, and 
adequate organ function, including normal calcium and 
magnesium. Ineligibility criteria included cardiac dysfunc-
tion, greater than grade 1 neuropathy or known sensitivity 
to carboplatin.
The trial was approved by site institutional review boards 
and was registered in clinicaltrials.gov (NCT 00687297).
Treatment
Patients were randomized before induction. For patients 
randomized to either arm, the 21-day cycles 1 through 4 
(induction) consisted of pretreatment with dexamethasone, 
then docetaxel, administered intravenously over 1 hour at a 
dosage of 75 mg/m2 on day 1, and carboplatin administered 
over 15 to 30 minutes at an area under the curve (AUC) of 6 
immediately following docetaxel on day 1, and 100 mg PO of 
vandetanib daily. Commercially available docetaxel and car-
boplatin were used.
Patients discontinued treatment for evidence of dis-
ease progression or unacceptable toxicity. Patients with 
improved or stable disease after four cycles could continue 
to the maintenance phase. During maintenance, patients 
received blinded study drug, either 300 mg/day of vande-
tanib or placebo PO. Maintenance therapy was administered 
until progression.
Safety was evaluated using National Cancer Institute 
Common Toxicity Criteria for Adverse Events, Version 3. 
Before each cycle, laboratory levels were checked, and a phys-
ical examination, including recording blood pressure, was 
conducted. An electrocardiograph was done at baseline, at 
3-month intervals, and at the end of treatment. Dosage modi-
fications for neutropenia, thrombocytopenia, hypertension, 
QTc prolongation, hepatic toxicity, edema, and skin toxicities 
were specified in the protocol.
Study Efficacy Endpoints and 
Assessment of Response
The goal of the trial was to study the combination of 
docetaxel + carboplatin and vandetanib, followed by mainte-
nance of vandetanib or placebo until disease progression, to 
determine whether active maintenance therapy could prolong 
PFS. PFS was defined as time from randomization to disease 
progression or death from any cause. Patients alive and dis-
ease free at the time of analysis were censored at the date of 
last disease evaluation. A secondary endpoint was overall 
response, measured using Response Evaluation Criteria in 
Solid Tumors19 Version1.0. OS was defined as time from ran-
domization to death. Patients alive at the time of this report 
were censored at the date of last contact.
Randomization and Masking
Randomization used permuted blocks within strata, 
where strata were combinations of sex (male versus female) 
and stage (IIIB versus IV/recurrent). Randomization code 
lists were prepared by the study statistician. Open-label van-
detanib and blinded study drug were shipped to each site for 
induction and maintenance, respectively. Bottle numbers for 
blinded study drug were allocated to vandetanib and placebo 
by the study statistician.
Statistical Methods
Standard therapy (docetaxel/carboplatin) was expected to 
confer median PFS of 4.6 months. The addition of vandetanib, 
with chemotherapy, and in addition, as maintenance therapy, 
would be considered worthy of further study if median PFS 
was 6.2 months or more. Assuming accrual of 7.25 eligible 
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patients per month for 21 months (152 total eligible patients), 
and 8 months of additional follow-up, the study would have 
90% power, using an exponential test with one-sided type I 
error of 10%. To allow for 5% ineligibility, a total accrual of 
160 patients was planned. Full information would exist when 
64 of 76 patients on either arm either progressed, or died. In 
case of improvement demonstrated over historical control 
for both arms, the added benefit conferred by maintenance 
vandetanib was to be evaluated using a stratified log-rank 
test among patients who received four cycles of induction. 
Full information required 73 progression events among an 
assumed 93 qualifying patients; there was 80% power to 
detect 50% improvement.
An interim safety analysis was planned after 15 patients 
completed induction. The design called for suspension if any 
of the following were observed: any grade 5 events, five or 
more unexpected events, or five or more treatment-related 
occurrences of grade 3 or higher of rash, diarrhea, hyperten-
sion, dehydration, or QTc prolongation.
Descriptive statistics were used to characterize patients 
at baseline. In addition to the analyses described above, there 
were protocol-specified analyses of outcomes by sex and age. 
We also constructed multivariate Cox proportional hazards 
models of PFS adjusting for significant prognostic factors. 
Mehta’s exact test for ordered categorical data (2-sided) 
was used to test for differences in toxicity profiles by arm. 
Stratified log-rank tests used actual assigned strata, even 
though there were some misstratified patients. Multivariable 
models used actual patient characteristics rather than stratifi-
cation factors.
RESULTS
Between May 30, 2008 and November 30, 2009, 162 
patients were enrolled by 26 institutions and randomized to 
induction followed by maintenance with either vandetanib, or 
placebo. Figure 1 shows disposition of cases (Consolidated 
Standards of Reporting Trials [CONSORT] diagram). Four 
patients withdrew before induction because of ineligibility (n 
= 2) or withdrawal of consent (n = 2). One hundred patients 
stopped treatment before maintenance; the remaining 58 
received maintenance vandetanib or placebo. Patients with-
out progression were followed through 1 year of maintenance. 
This report reflects the status of the database as of January 
28, 2011, when the database was locked and treatment of four 
remaining patients being treated was unblinded. One was 
receiving placebo and treatment was stopped. The remaining 
three patients remained on vandetanib maintenance. Median 
follow-up among patients still alive is 13.5 months.
Thirty patients did not meet eligibility criteria. The 
most common reason for ineligibility was missing or out-of-
range laboratory values (magnesium, potassium or calcium; 
n = 24). Other reasons included hypertension (n = 3), incorrect 
histology (n = 2), and superior vena cava syndrome (n = 1). 
Ineligible patients were included in all analyses.
Patient Characteristics
Baseline patient and disease characteristics are shown in 
Table 1. Median age was 63 years. The most common histology 
was adenocarcinoma. The proportion of patients with stage 
IV or recurrent disease was slightly higher than anticipated 
(91%). Seven patients with stage IV or recurrent disease (5 
on vandetanib maintenance, 2 on placebo maintenance) were 
incorrectly stratified as having stage IIIB disease. Both arms 
were well balanced with respect to this and other potentially 
prognostic factors.
Randomized
to
Vandetanib 
Maintenance
(n=80)
Randomized
to
Placebo
Maintenance
(n=82)
Withdrew Before 
Treatment (n=3)
Withdrew Consent (n=2)
Ineligible (n=1)
Withdrew Before
Treatment (n=1)
Ineligible (n=1)
Received 
Open-Label 
Induction 
(n=77)
Received
Open-Label
Induction
(n=81)
Off After Induction
Treatment
(n=45)
Adverse Events (n=16)
Patient Refusal (n=4)
Death (n=7)
Progressive Disease (n=17)
Other (n=1)
Off After Induction
Treatment
(n=55)
Adverse Events (n=15)
Patient Refusal (n=4)
Death (n=11)
Progressive Disease (n=20)
Other (n=5)
Received 
Blinded 
Maintenance
Vandetanib
(n=32)
Received
Blinded 
Maintenance
Placebo
(n=26)
Screened 
Patients
(n=162)
Off After Maintenance
Treatment
(n=29)
Progressive Disease (n=17)
Adverse Events (n=8)
Death (n=2)
Other (n=2)
Off After Maintenance
Treatment
(n=25)
Progressive Disease (n=20)
Adverse Events (n=4)
Other (n=1)
FIGURE 1.  Consolidated Standards of Reporting Trials 
(CONSORT) diagram.
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Treatment Administration
A median of three induction cycles was administered. 
The most common reasons for discontinuation during induc-
tion were disease progression (36%), adverse events (30%), 
and death during study (17%). Fifty-eight patients com-
pleted all four cycles of induction and began maintenance. 
Cumulatively, patients received 462 cycles of induction che-
motherapy. Of these, 346 were planned for delivery of carbo-
platin at AUC 6, 115 at AUC 5, and 1 at AUC 4, and 99% of 
cycles were delivered at the planned full dosage. Among 462 
cycles of docetaxel given, 340 were planned for 75 mg/m2, 115 
were planned for 60 mg/m2, two were planned for 45 mg/m2, 
and two were held. Almost all cycles (98.7%) were adminis-
tered at the planned full dosage. The most common reason 
for dosage adjustment was toxicity. Median dosage of van-
detanib administered during induction was 100 mg/day, the 
target dosage.
Among 32 patients randomized to vandetanib mainte-
nance and treated in the maintenance phase, a median of four 
cycles of maintenance was administered. The most common 
reasons for treatment discontinuation in this group were disease 
progression (59%) and adverse events (28%). Three patients 
were still receiving treatment at the time of database lock. 
Median dosage of vandetanib administered during maintenance 
to patients on this arm was 300 mg/day, the target dosage.
Among 26 patients randomized to placebo maintenance 
who began maintenance, a median of 2.5 cycles was delivered. 
Treatment was discontinued most commonly because of 
TABLE 1.  Baseline Patient and Disease Characteristics
Vandetanib Maintenance Placebo Maintenance Total
Total patients 80 82 162
Age, median (range) 63.5 (38–84) 63 (36–82) 63 (36–84)
Age, yr n (%) n (%) n (%)
 <50 10 (12.5) 6 (7.3) 16 (9.8)
 50–59 16 (20.0) 26 (31.7) 42 (25.9)
 60–69 34 (42.5) 23 (28.1) 57 (35.2)
 ≥70 20 (25.0) 27 (32.9) 47 (29.0)
Sex
 Male 42 (52.5) 42 (51.2) 84 (51.9)
 Female 38 (47.5) 40 (48.8) 78 (48.2)
Race/ethnicity
 White, non-Hispanic 66 (82.5) 72 (87.8) 138 (85.2)
 White, Hispanic 0 2 (2.4) 2 (1.1)
 Black, non-Hispanic 9 (11.3) 8 (9.8) 17 (9.3)
 Black, Hispanic 1 (1.3) 0 1 (0.5)
 Asian 1 (1.3) 0 1 (0.5)
 Native Hawaiian/Pacific Islander 1 (1.3) 0 1 (0.5)
 Other 2 (2.5) 0 2 (1.1)
Stage
 IIIB with malignant effusion 5 (6.3) 9 (11.0) 14 (8.6)
 IV 68 (85.0) 66 (80.5) 134 (82.7)
 Recurrent 7 (8.8) 7 (8.5) 14 (8.6)
ECOG PS
 0 27 (33.8) 34 (41.5) 61 (37.7)
 1 53 (66.3) 48 (58.5) 101 (62.4)
Histology
 Adenocarcinoma 46 (57.5) 48 (58.5) 94 (58.0)
 Squamous cell carcinoma 19 (23.8) 16 (19.5) 35 (21.6)
 Large cell carcinoma 4 (5.0) 0 4 (2.5)
 Bronchioalveolar 0 3 (3.7) 3 (1.9)
 Adenosquamous 2 (2.5) 2 (2.4) 4 (2.5)
 NSCLC, NOS 9 (11.3) 12 (14.6) 21 (13.0)
 Other 0 1 (1.2) 1 (0.5)
Smoking history
 Ever smoker (n = 161) 74 (92.5) 76 (93.8) 150 (93.2)
 Current smoker (n = 150) 15 (20.3) 32 (27.6) 36 (24.0)
ECOG, Eastern Cooperative Oncology Group; PS, performance status; NSCLC, non–small-cell lung cancer; NOS, not otherwise specified.
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disease progression (80%), although four patients (16%) 
discontinued placebo maintenance because of adverse events. 
One patient was still receiving placebo at the time of database 
lock. The difference in duration of maintenance treatment 
between arms was not statistically significant (2-sided 
Wilcoxon rank sum p = 0.62).
Adverse Events
All treated patients were assessed for adverse events 
every 21 days during induction, and every 28 days during 
maintenance. The protocol-specified interim safety analysis 
was conducted after the first 15 patients were followed long 
enough to complete induction (4 cycles). We found neither 
excess serious, unexpected adverse events, nor any higher-
than-expected incidence or severity of previously reported 
events, so the study continued. A second safety analysis 
was conducted at the request of the Data Safety Monitoring 
Board, after half the patients were enrolled long enough to 
complete four cycles of induction. After reviewing those 
data, the Data Safety Monitoring Board recommended con-
tinuation of the study.
Table 2 shows adverse events across all treatment 
phases, regardless of attribution, by grade and system organ 
class. Supplementary Tables 1 and 2 (Supplementary Digital 
Content, http://links.lww.com/JTO/A431) show adverse 
events of grade 3 and higher in more detail, for induction 
(treatment-related) and maintenance by arm. The distribution 
of worst-degree toxicities did not differ by arm (p = 0.93). 
Supplementary Table 3 (Supplemental Digital Content, http://
links.lww.com/JTO/A431) shows adverse events reported 
posttreatment.
There were seven grade 5 treatment-related events dur-
ing induction, including two infections, two hemorrhages, cen-
tral nervous system cerebrovascular ischemia, cardiac arrest, 
and a death described as acute cardiopulmonary arrest, likely 
secondary to progression of lung cancer and possible aspi-
ration. Four other patients died during induction of adverse 
events that were not considered treatment related: three from 
metabolic acidosis and one from dyspnea. Nine patients died 
of progressive disease during induction and two during main-
tenance therapy. In addition, one patient died of progressive 
disease within 30 days of the end of treatment.
We noted several patients for whom diverticulitis was 
reported. Because diverticulitis is not a recognized term in 
Common Toxicity Criteria for Adverse Events Version 3, we 
explored events in the gastrointestinal system in more detail. 
TABLE 2.  All Adverse Events Regardless of Attribution, by System, Organ, and Class
Randomized to  
Vandetanib Maintenance (n = 77)
Randomized to Placebo  
Maintenance (n = 81)
1 2 3 4 5 1 2 3 4 5
Allergy/immunology 4 5 1 2 — 3 3 2 — —
Auditory/ear 2 1 — — — 1 1 — — —
Blood/bone marrow 4 4 9 31 — 1 3 16 28 1
Cardiac arrhythmia 4 3 5 1 — 3 6 7 — —
Cardiac general 3 3 4 1 2 7 8 3 1 —
Constitutional symptoms 9 27 8 1 — 18 17 14 1 —
Coagulation — — — — — — — 2 — —
Dermatology/skin 12 23 13 1 — 11 28 5 2 —
Death — — — — 5 — — — — 6
Endocrine 2 — 1 — — 3 1 — — —
Gastrointestinal 17 29 15 2 — 17 20 25 1 —
Bleeding/bleeding 15 4 1 — — 7 3 1 — 2
Hepatobiliary/pancreas — — 1 — — — — 1 — —
Infection — 10 14 4 — 2 16 10 4 3
Lymphatics 5 6 — — — 9 4 1 — —
Metabolic/laboratory 18 5 12 — 1 9 7 15 3 1
Musculoskeletal/soft tissue 1 3 3 1 — 4 7 4 — —
Neurology 14 11 9 — 1 13 6 10 — —
Ocular/visual 3 1 — — — 7 3 — — —
Pain 15 16 10 2 - 10 19 15 — —
Pulmonary/upper respiratory 19 6 8 — 1 12 8 12 1 —
Renal/genitourinary 4 — 1 — 1 2 2 3 — —
Secondary malignancy — — 1 — — — — — — —
Sexual/reproductive function — 1 — — — 1 — — — —
Syndromes 1 — 1 — — — 2 — — —
Vascular 1 2 5 3 — 4 7 3 5 —
Worst degree 1 8 23 34 10 2 8 25 35 11
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Events considered to be potentially related to diverticulitis 
and observed at grade 3 or higher are summarized in Table 3. 
There were 96 patients affected, including all grades, and 32 
patients with events of grade 3 or 4. With regard to only this 
subset of events, the profile did not differ by arm (p = 0.71).
Progression-Free Survival
All 162 patients were included in the efficacy analy-
sis, which is essentially an evaluation of the combination 
of induction and maintenance between the two randomized 
groups. There were 149 events among these patients. Across 
both arms, median PFS was 4.5 months (95% confidence 
interval [CI], 3.6–4.9 months). This was not an improve-
ment over historical control rates, as initially hypothesized. 
PFS by arm is shown in Figure 2A. Median PFS among 
patients randomized to vandetanib maintenance was 4.5 
months (95% CI, 3.3–5.8 months), and among patients ran-
domized to placebo maintenance was 4.2 months (95% CI, 
2.8–4.9 months).
In an exploratory analysis done in the absence of a 
demonstrated improvement in PFS over historical controls, 
we tested the difference between arms, using a stratified log-
rank test. This difference calculated from randomization was 
statistically significant relative to the study’s planned type I 
error (stratified log-rank; p = 0.07). We also examined PFS in 
a multivariable model adjusted for sex and stage. The model is 
shown in Table 4. After this adjustment, patients randomized 
to vandetanib maintenance had improved PFS compared with 
patients randomized to placebo maintenance (hazard ratio = 
1.49; 95% CI, 1.07–2.07; Wald p = 0.02). ECOG PS and his-
tology were also tested in the model, but they did not contrib-
ute prognostic information.
Supplementary Figures 1 and 2 (Supplementary Digital 
Content, http://links.lww.com/JTO/A431) show PFS by arm, 
broken up by stage and sex, respectively. Women had lon-
ger PFS than men (median 5.1 versus 3.8 months; p = 0.04). 
Differences within treatment subgroups were not statistically 
significant, but the study was not powered to detect such 
differences.
Among the subset of patients who began maintenance 
therapy (essentially a landmark analysis examining the con-
tribution of maintenance vandetanib), there was no difference 
between the arms in PFS (stratified log-rank p = 0.46). The 
number of patients starting maintenance was, however, much 
lower than anticipated (58 versus 93).
Response
One complete response was observed at 15 months 
in a patient randomized to vandetanib maintenance. There 
were 14 partial responses at a median of 4.3 months among 
patients randomized to vandetanib maintenance and 15 partial 
responses at a median of 3.1 months among patients random-
ized to placebo maintenance. The overall response rate was 
18.5% (95% CI, 12.9%–25.4%).
Overall Survival
As of January 28, 2011, 105 patients had died. OS is 
shown in Figure 2B. Median OS among patients randomized 
to vandetanib maintenance was 9.8 months (95% CI, 7.3–15.7 
months). Median OS among patients randomized to placebo 
maintenance was 9.4 months (95% CI, 7.5–12.2 months). 
This difference was not statistically significant (stratified 
log-rank p = 0.68).
Supplementary Figures 3 and 4 (Supplemental Digital 
Content, http://links.lww.com/JTO/A431) show OS by 
treatment arm within stage and sex subgroups. Median OS was 
longer for women than for men (median 16.0 versus 8.2 months; 
log-rank p = 0.008). This effect reached statistical significance 
among patients randomized to placebo maintenance (median 
11.9 versus 7.5 months; log-rank p = 0.02) but not among 
those randomized to vandetanib maintenance (median 16.0 
versus 9.8 months; log-rank p = 0.17).
TABLE 3.  Adverse Events Potentially Associated with Diverticulitis
Randomized to  
Vandetanib Maintenance
Randomized to  
Placebo Maintenance
Grade 3 Grade 4 Grade 3 Grade 4
Abdomen, pain 1 — 2 —
Colitis 1 — — —
Colitis, infectious (e.g., C.diff) 1 – 1 –
Diarrhea without previous colostomy 9 – 10 –
Enteritis 1 — — —
Fistula, colon/cecum/appendix — — 1 —
Gastrointestinal, other — 1 1 —
Illeus — — 1 —
Muco/stomatitis by exam, oral cavity 3 — — —
Obstruction, ileum — — 1 —
Perforation, colon 1 — — —
Upper gastrointestinal, hemorrhage NOS 1 — 1 —
Worst degree 13 1 18 0
NOS, not otherwise specified.
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DISCUSSION
The study did not meet the protocol-specified end-
point of improvement over a hypothesized median PFS of 
4.6 months. One possible explanation for the poor outcome 
is that the patient population may have included a higher-
than-expected proportion of poor-risk patients. The historical 
control rate was estimated using the rate observed in the car-
boplatin/paclitaxel arm of the trial reported by Sandler et al.6 
Our patient population had a slightly lower proportion with 
stage IIIB disease (10 versus 13%), and also included patients 
with squamous carcinoma, which may have rendered the con-
trol rate optimistic. However, Belani et al.19 reported median 
time to progression of 5.4 months in a population of patients, 
24% of whom had stage IIIB disease.
The median PFS of 4.5 months observed among 
patients randomized to vandetanib maintenance is somewhat 
FIGURE 2. A, Progression-free 
survival by randomized maintenance 
arm. B, Overall survival by random-
ized maintenance arm.
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lower than that observed in other first-line studies. Heymach 
et al.20 conducted a randomized phase II study of first-
line carboplatin and paclitaxel with or without vandetanib 
in patients with advanced NSCLC. The study also had a 
vandetanib monotherapy arm that closed early because of 
lack of efficacy. In both vandetanib arms, the drug was given 
at 300 mg/day. As in our study, 90% of patients had stage IV 
disease. The authors observed longer PFS when vandetanib 
was added to carboplatin and paclitaxel (median PFS 5.5 
versus 5.3 months; log-rank p = 0.09). Although the study 
had no explicit maintenance phase, the authors observed, 
“the PFS benefit was mainly observed among patients treated 
for more than 4 months, suggesting that post-chemotherapy 
maintenance therapy may have contributed to the benefit.” 
The higher dosing of vandetanib during induction (300 mg/
day compared with 100 mg/day in our study) may also have 
contributed to their more favorable outcome, although the 
100-mg dosage had been shown in another randomized phase 
II study to have efficacy similar or somewhat superior to the 
300-mg dosage when given with docetaxel to previously 
treated patients.17
The lack of improvement in OS is consistent with recent 
reports showing no evidence of a survival improvement with 
vandetanib in NSCLC (e.g., ZEAL,21 ZEPHYR,22 ZEST,23 
ZODIAC).24 Similarly, recent reports of other targeted thera-
pies in NSCLC have failed to demonstrate improved survival 
(e.g., BeTa,15 NExUS,25 ESCAPE,26 MONET127), despite 
showing improved PFS (e.g., ATLAS),16 Our study was not 
powered to detect a survival difference.
We did not meet the protocol-specified condition for 
testing for differences in PFS between patients who began 
vandetanib maintenance and those who began placebo 
maintenance. However, fewer patients reached maintenance 
than expected, and our statistical power to detect differences 
in the PFS was compromised. In our exploratory analysis, 
prolonged PFS was demonstrated among patients random-
ized to vandetanib maintenance, using a multivariable 
model adjusting for sex and stage. Therefore, our favorable 
comparison of PFS for vandetanib among patients starting 
maintenance on the two arms should be viewed as hypoth-
esis generating.
The observed toxicity profile was similar to that seen in 
other trials of cytotoxic chemotherapy in combination with 
VEGF-targeted therapy. Although there were few events of 
grade 4 or more during maintenance, adverse events need 
to be considered when evaluating risks and benefits of van-
detanib maintenance. Across all phases of treatment, we 
observed no hemoptysis, one grade 5 treatment-related 
hemorrhage, and a grade 5 lung hemorrhage, felt to reflect 
disease progression. We explored adverse events related to 
diverticulitis and found that rates were similar between arms. 
The lack of a defined term for diverticulitis, however, may 
impede its recognition as a side effect in treatments with tar-
geted therapies.
The proportion of patients who continued to the main-
tenance phase was lower than expected (38 versus 61%). 
Approximately a quarter of the patients withdrew during or after 
induction because of adverse events. In retrospect, protocol cri-
teria for withdrawal may have been more stringent than neces-
sary. For example, bilirubin above the institution’s upper limit 
of normal triggered a dosage reduction, and only one dosage-
level reduction was permitted for vandetanib during induction.
The study’s ineligibility rate was higher than expected, 
specifically related to missing or out-of-range values for mag-
nesium, potassium, or calcium. In retrospect, the requirements 
may have been stricter than necessary to assure patient safety, 
although seven patients experienced grade 3 and 4 treatment-
related adverse events related to low levels of the laboratories, 
and four of these patients were ineligible because of low levels 
at baseline.
In 2009, Hanrahan et al.28 reported that patients with 
low baseline blood levels of VEGF were more likely to ben-
efit from vandetanib therapy. If confirmed prospectively, this 
might serve as a biomarker in identifying patients for whom 
vandetanib therapy might be beneficial. Similarly, EGFR 
mutation status is a known prognostic or predictive factor. 
However, no blood samples were collected on this trial to per-
mit exploration of these biomarkers.
There is a growing body of evidence that maintenance 
targeted therapy improves PFS in patients with NSCLC.29 
We conclude that vandetanib may also have a role as mainte-
nance therapy for patients with NSCLC treated with cytotoxic 
chemotherapy. Further studies exploring risks, benefits, and 
potential predictive markers seem justified.
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